Sustained Release of Nanoformulation of Diethyl Carbamazine (Dec) for Filariasis – a Review

  • Authors

    • D Yuvaraj
    • P Jai Preethi
    • A Saravanan
    • K H. Smila
    2018-09-01
    https://doi.org/10.14419/ijet.v7i3.34.19354
  • Filariasis, nanopharmaceuticals, Liposomes, Diethylcarbamazine

  • Lymphatic filariasis (LF), is a mosquito vector-borne disease and a major public health problem in the tropical countries. The annual mass drug administration (MDA) in India was studied in 1996-97. It was introduced with single dose of Diethylcarbamazine and was investigated  as a pilot project covering 41millon population. The study was extended to 77million population by 2002. The MDA is one of the strategies to eliminate LF in India. Liposomes, polymeric and solid lipid nanoparticles are the most promising nanopharmaceuticals which are easy to formulate, cheaper and can bring prolific consequences for filariasis management.

     

     

  • References

    1. [1] Rao U.R, K.C.Nagodavithana, Samarasekera S.D,Wijegunwardana A.D, Premakumara W.D.Y, et al. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of Mass Drug Administration, PLOs neglected tropical disease.2014:8(11)

      [2] Om Prakash Sharma, Yellamandaya Vadlamudi, Arun Gupta Kota, Vikrant Kumar Sinha & Muthuvel Suresh Kumar. Drug targets for lymphatic filariasis: a bioinformatic approach, review article.J vector Borne Dis.2013:155-162

      [3] Gurjeet Singh, Raksha, A.D. Urhekar. Advanced techniques for detection of filariasis-a riew. Int.J.Research studies in biosciences(IJRSB).2013:(1)17-22

      [4] Ali M., Afzal M., Bhattacharya S.M., Ahmad F.J., Dinda A.K. Nanopharmaceuticals to target antifilarials: a comprehensive review. Expert Opin. Drug Deliv. 2013;10:665–678.

      [5] Balaure P.C., Andronescu E., Grumezescu A.M., Ficai A., Huang K.S., Yang C.H., Chifiriuc C.M., Lin Y.S. Fabrication, characterization and in vitro profile based interaction with eukaryotic and prokaryotic cells of alginate–chitosan–silica biocomposite. Int. J. Pharm. 2013;441:555–561.

      [6] Filippousi M., Papadimitriou S.A., Bikiaris D.N., Pavlidou E., Angelakeris M., Zamboulis D., Tian H., Van Tendeloo G. Novel core–shell magnetic nanoparticles for Taxol encapsulation in biodegradable and biocompatible block copolymers: preparation, characterization and release properties. Int. J. Pharm. 2013;448:221–230.

      [7] Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (Lond.) 2013;9:1–14.

      [8] Liu Y., Solomon M., Achilefu S. Perspectives and potential applications of nanomedicine in breast and prostate cancer. Med. Res. Rev. 2013;33:3–32.

      [9] Saraceno R., Chiricozzi A., Gabellini M., Chimenti S. Emerging applications of nanomedicine in dermatology. Skin Res. Technol. 2013; 19:e13–e19.

      [10] Tan S., Li X., Guo Y., Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale. 2013;5:860–872.

      [11] Hirsjarvi S., Passirani C., Benoit J.P. Passive and active tumour targeting with nanocarriers. Curr. Drug Discov. Technol. 2011;8:188–196.

      [12] Grumezescu A.M., Vasile B.S., Holban A.M. Eugenol functionalized magnetite nanostructures used in anti-infectious therapy. Lett. Appl. Nanobiosci. 2013;2:120–123.

      [13] Pavani K.V., Srujana N., Preethi G., Swati T. Synthesis of copper nanoparticles by aspergillus species. Lett. Appl. Nanobiosci. 2013;2:110–113.

      [14] Mignani S., Kazzouli S.E., Bousmina M., Majorale J.P. Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry. Prog. Polym. Sci. 2013;38:993–1008.

      [15] Song Q., Wang X., Hu Q., Huang M., Yao L., Qi H., Qiu Y., Jiang X., Chen J., Chen H., Gao X. Cellular internalization pathway and transcellular transport of pegylated polyester nanoparticles in Caco-2 cells. Int. J. Pharm. 2013;445:58–68.

      [16] Azzopardi E.A., Ferguson E.L., Thomas D.W. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J. Antimicrob. Chemother. 2013;68:257–274.

      [17] Jang S.C., Gho Y.S. Could bioengineered exosome-mimetic nanovesicles be an efficient strategy for the delivery of chemotherapeutics? Nanomedicine (Lond.) 2014;9:177–180.

      [18] Jain N.K., Mishra V., Mehra N.K. Targeted drug delivery to macrophages. Expert Opin. Drug Deliv. 2013;10:353–367.

      [19] Vyas H., Upadhyay T., Thakkar N., Patel K., Upadhyay U. Nanocochleate: novel bypass of conventional drug delivery system. Pharma. Tutor. 2014;2:90–97.

      [20] Kamboj S., Saini V., Maggon N., Bala S., Jhawat V. Vesicular drug delivery systems: a novel approach for drug targeting. Int. J. Drug Deliver. 2013;5:121–130.

      [21] Goudanavar P. Manjunatha; Hiremath, D. Development and charactarization of perindopril erbumine loaded ethanolic liposomes. Lett. Appl. Nanobiosci. 2014;3:151–157.

      [22] Shi P., Gustafson J.A., MacKay J.A. Genetically engineered nanocarriers for drug delivery. Int. J. Nanomedicine. 2014;9:1617–1626.

  • Downloads

  • How to Cite

    Yuvaraj, D., Jai Preethi, P., Saravanan, A., & H. Smila, K. (2018). Sustained Release of Nanoformulation of Diethyl Carbamazine (Dec) for Filariasis – a Review. International Journal of Engineering & Technology, 7(3.34), 439-441. https://doi.org/10.14419/ijet.v7i3.34.19354